With Global Horizon, Chinese Angle strategy, BOCG strives to support true innovation and disruptive technology of life science.
Accumulated 100+ years’ experience and US$ 1+ billion proven record, the BOCG veteran team builds its office and franchise in Shenzhen, Shanghai, Hong Kong, and Gothenburg of Sweden, and extensive networks and footprint in Greater China, Asia, USA and Europe.
A signatory to the UN PRI and committed to promoting sustainable development and impact investment.
On January 10th, 2025, BOCG's portfolio company, Ribo Life Science, with its subsidiary, Ribocure Pharmaceuticals AB, announced that they have achieved a key pre-clinical milestone in their siRNA programs, less than a year into their collaboration with Boehringer Ingelheim with an overall deal value that exceeds USD 2 billion.
On December 6, 2024, the 7th Venture Capital Responsible Investment Forum was successfully held in Lujiazui, Shanghai. Frank Yang, Founding Partner and CEO of BOCG, was invited to join the roundtable discussion on “Healthcare Innovation and Well-Being”, engaging in in-depth dialogue with fellow participants.
Recently, BOCG's portfolio company, Ribo Life Science, announces that it received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the lipid-lowering siRNA drug RBD5044 that targets APOC3.
